{
    "root": "6a9f9dd4-858e-4dd0-baf5-4b686d58fbeb",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Eplerenone",
    "value": "20200827",
    "ingredients": [
        {
            "name": "EPLERENONE",
            "code": "6995V82D0B"
        },
        {
            "name": "LACTOSE, UNSPECIFIED FORM",
            "code": "J2B2A4N98G"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        }
    ],
    "indications": "eplerenone aldosterone antagonist indicated : • improving survival stable patients symptomatic heart failure reduced ejection fraction ( hfref ) acute myocardial infarction . ( 1.1 ) • treatment hypertension , lower blood pressure . lowering blood pressure reduces risk fatal nonfatal cardiovascular events , primarily strokes myocardial infarctions . ( 1.2 )",
    "contraindications": "hfref post-myocardial infarction : initiate treatment 25 mg daily . titrate maximum 50 mg daily within 4 weeks , tolerated . dose adjustments may required based potassium levels . ( 2.1 ) hypertension : 50 mg daily , alone combined antihypertensive agents . inadequate response , increase 50 mg twice daily . higher dosages recommended . ( 2.2 ) patients : measure serum potassium starting eplerenone periodically thereafter . ( 2.3 )",
    "warningsAndPrecautions": "eplerenone tablets yellow , diamond biconvex , film-coated . debossed `` g `` one side . supplied follows : dose deboss side 2 ndc 59762-xxxx-x bottle/30 bottle/90 unit dose abbreviation : na=not applicable 25 mg 25 1710-2 1710-3 1710-1 50 mg 50 1720-1 1720-2 na",
    "adverseReactions": "patients : • serum potassium > 5.5 meq/l initiation ( 4 ) • creatinine clearance ≤30 ml/min ( 4 ) • concomitant strong cyp3a inhibitors ( 4 , 7.1 ) treatment hypertension : • type 2 diabetes microalbuminuria ( 4 ) • serum creatinine > 2.0 mg/dl males , > 1.8 mg/dl females ( 4 ) • creatinine clearance < 50 ml/min ( 4 ) • concomitant potassium supplements potassium-sparing diuretics ( 4 )",
    "indications_original": "Eplerenone is an aldosterone antagonist indicated for: • Improving survival of stable patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction. ( 1.1 ) • The treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.2 )",
    "contraindications_original": "HFrEF Post-MI : Initiate treatment with 25 mg once daily. Titrate to maximum of 50 mg once daily within 4 weeks, as tolerated. Dose adjustments may be required based on potassium levels. ( 2.1 ) Hypertension : 50 mg once daily, alone or combined with other antihypertensive agents. For inadequate response, increase to 50 mg twice daily. Higher dosages are not recommended. ( 2.2 ) For all patients: Measure serum potassium before starting eplerenone and periodically thereafter. ( 2.3 )",
    "warningsAndPrecautions_original": "Eplerenone tablets are yellow, diamond biconvex, and film-coated. They are debossed with \"G\" on one side. They are supplied as follows:\n                  \n                     \n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                              Dose\n                           \n                           \n                              Deboss Side 2\n                           \n                           \n                              NDC 59762-xxxx-x\n                           \n                        \n                        \n                           \n                              Bottle/30\n                           \n                           \n                              Bottle/90\n                           \n                           \n                              Unit dose\n                           \n                        \n                     \n                     \n                        \n                           Abbreviation: NA=not applicable\n                        \n                     \n                     \n                        \n                           \n                              25 mg\n                           \n                           \n                              25\n                           \n                           \n                              1710-2\n                           \n                           \n                              1710-3\n                           \n                           \n                              1710-1\n                           \n                        \n                        \n                           \n                              50 mg\n                           \n                           \n                              50\n                           \n                           \n                              1720-1\n                           \n                           \n                              1720-2\n                           \n                           \n                              NA",
    "adverseReactions_original": "For all patients: • Serum potassium >5.5 mEq/L at initiation ( 4 ) • Creatinine clearance ≤30 mL/min ( 4 ) • Concomitant use with strong CYP3A inhibitors ( 4 , 7.1 ) For the treatment of hypertension: • Type 2 diabetes with microalbuminuria ( 4 ) • Serum creatinine >2.0 mg/dL in males, >1.8 mg/dL in females ( 4 ) • Creatinine clearance <50 mL/min ( 4 ) • Concomitant use of potassium supplements or potassium-sparing diuretics ( 4 )"
}